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Background: Early onset chronic inflammation is present in CF. Platelets may contribute to inflammation by cytokine release and interaction with
leukocytes.
Methods: Parameters of platelet proinflammatory function (soluble CD62P, soluble CD40L, the percentage of platelet–leukocyte aggregates,
platelet CD62P) and platelet procoagulatory function (PAC-1-binding to activated integrin αIIbβ3 and expression of integrin αIIbβ3=CD41a) were
measured in patients and controls.
Results: Levels of sCD62P, sCD40L were increased in CF irrespective of age and activity of inflammation. The number of platelet–leukocyte
aggregates was elevated in older CF patients. PAC-1-binding to platelets decreased with growing activity of inflammation. Exocytosis of CD41a
upon platelet activation was reduced.
Conclusion: In CF, platelet proinflammatory activity is increased at very young age already and might promote inflammation and tissue damage.
On the other hand, platelets seem to downregulate the activation of their most important integrin (αIIbβ3) for clot formation.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Background
Cystic fibrosis (CF) is a chronic multiorgan disorder caused
by mutations in the CFTR (cystic fibrosis transmembrane
conductance regulator) gene. Dysfunction of the CFTR protein
results among others in the production of dehydrated airway
secretions and an impaired mucociliary clearance [1]. Thus
chronic, mainly pulmonary inflammation is present in patients
with CF and starts at very young age [2]. Damage to lung tissue
causes an impaired pulmonary function and respiratory failure
is the most common cause of death in CF. Neutrophil
recruitment to the lungs is the most important contributor to
pulmonary destruction [3]. However, there is evidence, that
platelets, too, have an important role in the pathogenesis of
inflammation. They release a variety of cytokines and also⁎ Corresponding author. University Children's Hospital, Josef-Schneider Straße 2,
7080 Würzburg, Germany. Tel.: +49 931 201 27915; fax: +49 931 201 27242.
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91569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.12.004facilitate leukocyte recruitment to the sites of inflammation
by direct interaction with leukocytes and endothelium [4–7].
P-selectin glycoprotein ligand 1 (PSGL-1) and integrin αMβ2
(CD11b/CD18) are the most important leukocyte proteins
involved in binding to platelets and endothelium [4,8]. Platelet
P-selectin–PSGL-1 interaction seems to be involved in the
upregulation and activation of the leukocyte adhesive integrin
αMβ2 [9].
Circulating platelet–leukocyte aggregates (PLAs) in whole
blood reflect platelet activation and platelet binding to
leukocytes. The percentage of PLAs was shown to be elevated
in a variety of vascular and inflammatory disorders [5,10].
Based on the knowledge about the contribution of platelets to
inflammation and leukocyte recruitment, the contribution of
platelets and PLAs to inflammation in CF has been investigated
in previous studies including mainly older children and adults.
These studies found platelet hyperaggregability, an increased
formation of PLAs, an elevation of the platelet-derived
proinflammatory cytokines and other signs of an upregulation
of platelet proinflammatory functions [5,11,12].d by Elsevier B.V. All rights reserved.
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answered especially in young CF patients. It is unclear whether
very young children with CF already show alterations of platelet
proinflammatory functions. Furthermore, most studies included
both clinically stable and acutely exacerbated patients with CF.
Thus, previous results might have been strongly influenced by
effects of acute infections and may therefore not reflect
pathophysiological mechanisms in CF patients with a stable
state of disease. Reflecting previous data we hypothesized that
activation of platelet proinflammatory and procoagulatory
functions might already be present in very young children and
might aggravate with growing age and progressive inflamma-
tion. In this study we investigated platelet function in clinically
stable patients with CF to rule out an influence of acute
exacerbation. We compared platelet function among young
children and older patients with CF and among patients with
different activity of inflammation to determine the onset of
platelet function alterations and its dependence on chronic
inflammation.
2. Methods
2.1. Patients, controls and blood sampling protocol
The study was approved by the local ethics committee.
After written informed consent was obtained, blood was taken
from 54 consecutive patients with confirmed CF (age 16.4±
8.9 years; range 3 to 41 years) seen in the CF clinic of the
University Children's Hospital at Wuerzburg as well as from 55
healthy age and sex-matched controls (age 16.1±9.0 years;
range 3 to 41 years). All CF patients were recruited from the
same centre and were treated according to the same standards
but dependent on their stage of disease. 12 patients received
systemic steroids, 8 patients were on β-lactam antibiotics. All
patients were in a clinically stable state of disease as assessed by
the CF-specialist physician. All records were carefully
reviewed. Four initially included patients had to be excluded,
three due to viral infections, one due to thrombocytopenia
caused by hypersplenism.
In a subsequent study, we investigated platelet expression of
CD41a and leukocyte expression of PSGL-1 and integrin αMβ2
in 15 stable CF patients (age 25.7±7.6 years) and 14 healthy
controls (age 27.4±8.2 years).
2.2. Characterization of patients, controls and definition of
subgroups
As chronic inflammation aggravates with growing age,
patients and controls were divided into subgroups of young
and old individuals using the patients' age median of 15 years
as cut-off. CRP, IgG and fibrinogen levels were measured in
all patients and controls with commercially available kits from
Roche Diagnostics (Grenzach, Germany) and Dade Behring
(Marburg, Germany). Levels of CRP and IgG have been
shown to be suitable markers of inflammation in CF pre-
viously [13–15]. Pulmonary function and Chrispin–Norman
(CN)-score were recorded from the patients' files. To compareplatelet function in old patients with different activity of
chronic inflammation they were further divided into subgroups
with normal and elevated CRP/IgG using the 97th percentile
in the age-matched controls as cut-off. This cut-off level was
0.46 mg/dl for CRP and 1400 mg/dl for IgG. The patients in
the high CRP group were not completely identical to the
patients in the high IgG group (n=11 both). As none of the
young patients showed elevated CRP or IgG levels, only old
patients were included in these subgroups to rule out age bias.
Thus we were forced to use another strategy to investigate the
influence of chronic inflammation on platelet function at
young age: Subgroups of young patients were formed using
the 50th percentile of their CRP levels (0.04 mg/dl) as cut-off.2.3. Flow cytometric analysis of platelets in platelet-rich
plasma (PRP)
PRP was obtained from citrate-anticoagulated whole blood
by centrifugation at no more than 142 g to minimize in-vitro
platelet activation. 160 µl PRP were incubated with either 40 µl
phosphate buffered saline (PBS) or 40 µl thrombin-receptor-
activating peptide (TRAP-6, 10 µM final) for 10 min. 5 µl anti-
CD62P-FITC, anti-PAC-1-FITC or the appropriate isotype
controls were added to 10 µl of PRP (±TRAP-6). 20 min
later the samples were diluted with 250 µl PBS containing 1%
formaldehyde and analysed in a FACScan flow cytometer
(Becton Dickinson, Heidelberg, Germany). Platelets were iden-
tified by FSC-SSC-characteristics. The percentage of P-selectin
(CD62P) and PAC-1-positive platelets was defined as fraction
binding the specific antibody minus the fraction binding the
isotype control. TRAP-6 was purchased from Bachem (Weil a.
Rhein, Germany).2.4. Enzyme-linked immunoassays
Plasma soluble P-selectin (sCD62P) and soluble CD40
ligand (sCD40L) were measured by commercially available
ELISA kits (R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany) in platelet poor plasma (centrifugation at 3540 g for
10 min) frozen at −70 °C. After thawing, plasma was diluted
1:15 (sCD62P) or 1:5 (sCD40L) and processed following the
manufacturer's instructions. Results were calculated by inter-
polation from a standard curve.2.5. Platelet–leukocyte aggregates
Whole blood was diluted 1:1 with PBS. 10 µl were incubated
with 5 µl anti-CD45-FITC or isotype control and 5 µl anti-
CD41a-PE for 20 min. Samples were diluted with 250 µl FACS
lysing solution for lysis of erythrocytes. Monocytes and
neutrophils were identified by CD45-binding and their FSC-
SSC-characteristics. CD41a-positive events within the neutro-
phil or monocyte population (PLAs) were expressed as percent
of the totally counted number of neutrophils and monocytes.
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14 controls
In 15 patients and 14 controls additional investigations were
performed: 80 µl of citrate-anticoagulated whole blood were
incubated with PBS or TRAP-6 (10 µM final) for 10 min.
Antibodies were added to 10 µl of whole blood (±TRAP-6).
5 µl of anti-CD41a-PE were used to measure platelet CD41a-
expression before and after activation with TRAP-6. CD41a-
expression is shown as mean fluorescence intensity (MFI). For
measuring PSGL-1 and integrin αMβ2 expression on leukocyte
subpopulations either engaged in PLAs or not, whole blood
(+PBS) was incubated with 3 µl of anti-CD45-FITC, 5 µl of
anti-CD162-PE, anti-CD11b-PE, respectively, or the appropri-
ate PE-conjugated isotype control and 3 µl of anti-CD41a-
PerCP-Cy-5.5. Leukocytes were identified by CD45-expression
and their characteristic FSC-SSC-properties. PLA were defined
as CD41a positive events within the leukocyte population. The
MFI of the isotype control was subtracted from the MFI of
specific antibody binding to calculate PSGL-1 and integrin
αMβ2-expression. To exclude day-to-day variability MFI of PE-
labelled beads was measured daily and MFI of antibody binding
was normalized to a bead MFI of 500. All antibodies, beads and
FACS lysing solution were purchased from Becton Dickinson
(Heidelberg, Germany). Samples were analysed on a FACScan
flow cytometer from Becton Dickinson (Heidelberg, Germany).
2.7. Data analysis
Since several variables of interest were not normally distributed,
non-parametric tests were used for statistical analysis. Consequent-
ly, data are reported as median and range. A type I error of pb0.05
was considered to indicate a statistical significance. The groups of
young and old patients with CF, and young and old controls were
compared primarily using Kruskal–Wallis test. In case of
significant differences among the groups, 5 planned comparisons
were performed using Mann–Whitney U-test with p adjusted
according to Bonferroni: CF-patients vs. controls, young patients
vs. old patients, young controls vs. old controls, young patients vs.
young controls, old patients vs. old controls. Analyses within the
subgroups of young or old patients with CF (low vs. highCRP, low
vs. high IgG) were performed using Mann–Whitney U-test.
Likewise, in the subsequent study on 15 patients and 14 controls
comparison between the two groups was done employing Mann–
WhitneyU-test. The relationship between the age and investigated
variables was assessed using Spearman rank correlation analysis.
r≥0.3 (or r≤−0.3) and pb0.05 was considered to indicate a
correlation. Fisher's exact test was used to determine whether the
number of patients colonised with bacteria or on systemic steroids
was significantly different in young and old patients.
3. Results
3.1. Patient data, parameters of inflammation
Platelet counts, the number of patients colonised with pseu-
domonas or staphylococcus aureus, levels of C-reactive protein(CRP) and immunoglobulin G (IgG), neutrophil counts,
fibrinogen, vital capacity (VC), forced exspiratory volume in
1s (FEV1) and chest X-ray findings (CN-score) of patients and
controls as well as their correlation with age are shown in
Table 1. Platelet counts were similar in all four subgroups. CRP,
IgG, fibrinogen levels and CN-score were higher, pulmonary
function was worse in old compared to young patients. FEV1
was significantly lower, CN-score, CRP and IgG levels were
significantly higher in the pseudomonas positive subgroup (data
not shown). There was no difference of any other parameter
(descriptive or analysed) in the subgroups positive or negative
for pseudomonas and staphylococcus aureus, respectively.
Comparing patients positive for any of the two bacteria with
patients not colonised with these bacteria revealed a significant
difference for CN-score and IgG levels only, but not for any of
the analysed platelet parameters (data now shown).
Neutrophil counts were higher in the 12 patients on systemic
steroids (pb0.001). None of the other descriptive parameters
were different in the patients with or without steroids or β-
lactam antibiotics.
3.2. Platelet function
3.2.1. Soluble markers of platelet activation
CF patients had significantly higher levels of plasma soluble
CD62P and CD40 ligand (Fig. 1 and Table 2). The levels were
unrelated to age. Even very young children with CF (age range
3–7 years; n=8) showed significantly elevated levels of
sCD62P (median 49 ng/ml vs. 34 ng/ml) and sCD40L (median
692 pg/ml vs. 180 pg/ml) compared to age-matched controls
(pb0.05). The levels of sCD40L were significantly lower in
patients on systemic steroids (median 217 pg/ml vs. 441 pg/ml;
p=0.017). None of the other analysed platelet parameters were
different between the patients with or without systemic steroids
or β-lactam antibiotics.
3.2.2. Platelet–leukocyte aggregates (PLAs)
Firstly, the percentage of PLAs (shown as platelet–
neutrophil and platelet–monocyte aggregates) was significantly
increased in all CF patients vs. all controls and in old CF
patients vs. old controls. Secondly, the number of PLAs was
higher in young controls than in old controls, but not
significantly different compared to young patients (see
Table 2). And thirdly, in controls, the number of platelet–
neutrophil and platelet–monocyte aggregates correlated with
age (see Fig. 1). These three points show, that the physiological
decrease of PLAs with growing age, as seen in controls, was not
present in CF patients. The number of PLAs was not different
between patient subgroups.
3.2.3. CD62P expression
As shown in Table 2, there was no significant difference of
CD62P positive platelets before and after in-vitro-stimulation in
any patient or control subgroup. CD62P-positive platelets
(without TRAP-stimulation) correlated with the patients' age
(r=−0.39; p=0.004).
Table 1
Characterization of patients and controls subgroups.
Parameter Young
patients
Old patients Correlation
with age
Young
controls
Old controls Correlation
with age
Kruskal–Wallis
Age range
(age mean±SD)
years 3–14 (9.2±4.0) 15–41 (22.9±7.5) r=(pb0.05) 3–14 (9.4±3.8) 15–41 (22.3±7.5) r=(pb0.05) p
n=26 n=28 n=26 n=29
C-reactive protein mg/dl 0.04*
(0.01–0.36)
0.33*†
(0.01–5.51)
0.62 0.04*
(0.01–0.22)
0.07*†
(0.01–0.51)
0.47 b0.001
Immunoglobulin G mg/dl 897*
(491–1308)
1395*†
(773–3722)
0.74 928
(653–1450)
1056†
(742–1582)
0.35 b0.001
Neutrophil count /µl 4067§*
(2205–13040)
6672§*†
(2506–19662)
– 3332§
(643–5607)
3534§†
(2275–6764)
– b0.001
Monocyte count /µl 508
(207–1620)
465
(75–1078)
– 409*
(184–623)
490*
(301–1140)
– 0.002
Platelet count 103/µl 320
(218–471)
307
(105–534)
– 305
(214–429)
280
(190–368)
– 0.022
Fibrinogen g/l 3.0§*
(2.1–4.5)
3.9§*†
(2.1–8.2)
0.38 2.5§
(1.4–4.0)
2.5§†
(1.2–4.0)
– b0.001
VC % 89
(65–132)
73
(34–120)
−0.32 – – – 0.082
FEV 1 % 99*
(47–119)
60*
(21–128)
−0.61 – – – b0.001
CN-score 6*
(2–15)
17*
(4–29)
0.78 – – – b0.001
Pseudomonas positive (no.) 4$ 18$ – – – – –
S. aureus positive (no.) 12 11 – – – – –
Systemic steroids (no.) 3 9 – – – – –
Data are shown as median and range.
VC, vital capacitance; FEV1, forced 1 second expiratory volume. p-values resulting from the Kruskal–Wallis test are indicated (pb0.05 was considered statistically
significant).
§indicates significantly different values in all patients compared to all controls; ⁎ indicates significantly different values in the older and younger subgroup; † indicates
significantly different values in subgroups of patients and controls (pb0.01; Bonferroni-corrected Mann–Whitney U-test). Correlations of parameters with age are
shown, if present. r≥0.3 (or r≤−0.3) and pb0.05 (Spearman rank correlation) was considered to indicate a correlation. $ indicates a significant difference assessed
by Fisher's exact test (pb0.001).
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proinflammatory platelet function in any of the studied
parameters (Table 3). Likewise, colonization with P. aerugi-
nosa and/or S. aureus did not impact proinflammatory function
of platelets (data not shown).
3.2.4. PAC-1-binding
Baseline PAC-1-binding to (unstimulated) CF platelets was
clearly decreased. The activation of the integrin αIIbβ3 after
TRAP-stimulation was also lower in patients. These results and
differences in subgroups are shown in Fig. 2. PAC-1-binding
decreased with growing activity of inflammation. PAC-1-
binding correlated with the patients' age (r=−0.31; p=0.02).
Except of the latter and the above mentioned CD62P-positive
platelets, none of the investigated parameters correlated with the
patients' or controls' age.
3.2.5. CD41a expression
In a subsequent study we measured platelet CD41a
expression (integrin αIIbβ3 regardless of its conformational
state) on resting and TRAP-6-activated platelets in 15 CF
patients and 14 controls. This parameter (MFI) was significantly
decreased in CF patients after TRAP-6-stimulation of platelets
(655, range 405–899 vs. 758, range 470–1186). BaselineCD41a expression was identical in patients and controls (241,
range 161–384 vs. 262, range 201–367).
3.3. Leukocyte expression of PSGL-1 and CD11b
Furthermore, we subsequently investigated PLAs and
leukocyte expression of PSGL-1 and integrin αMβ2 (CD11b)
in 15 patients and 14 controls. As observed in the previous study
group PLAs were elevated in CF (data not shown). Furthermore,
CD11b was significantly higher expressed on CF neutrophils
(542, range 284–1210 vs. 310, range 146–929; p=0.009) and
CF monocytes (820, range 512–2046 vs. 478, range 238–898;
pb0.001) compared to controls. Leukocyte PSGL-1 expression
was identical in patients and controls (neutrophils: 387, range
248–474 vs. 355, range 284–499; p=0.896 and monocytes:
600, range 392–704 vs. 616, range 434–755; p=0.275). There
was no difference of PSGL-1 and CD11b expression between
leukocytes engaged in PLAs or not (data not shown).
4. Discussion
In this study, alterations of platelet function and platelet–
leukocyte interactions were investigated in patients with CF at
different ages, including a significant number of young children
Fig. 1. Soluble markers of platelet activation and platelet–leukocyte aggregates. Soluble P-selectin (sCD62P), soluble CD40 ligand (sCD40L), percentage of platelet–
neutrophil and platelet–monocyte aggregates of patients (▲) and controls (○) are plotted over the age. $ Percent of platelet-positive neutrophils/monocytes are shown
relatively to the number of totally counted neutrophils/monocytes. r- and p-values as determined by Spearman Rank correlation are indicated. In controls, there was a
significant correlation of platelet–neutrophil and platelet–monocyte aggregate counts with the age.
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proinflammatory activity was present in young children already
and how it changed with growing age and increasing activity of
inflammation. Unlike previous studies, only clinically stableTable 2
Platelet proinflammatory function in young and old patients and controls subgroups
Parameter Young patients Old
Age range years 3–14 15–
n=26 n=2
Soluble CD62P ng/ml 42.6§†
(22.4–67.8)
40.8
(25.
Soluble CD40L pg/ml 441§†
(81–1444)
345§
(57–
Platelet–neutrophil ag. %$ 30§
(5–85)
24§†
(6–8
Platelet–monocyte ag. %$ 76§
(13–92)
66§†
(15–
CD62P %$ 0.6
(0.0–14.5)
0.5
(0.0–
CD62P+TRAP %$ 39.1
(0.8–52.1)
40.9
(2.0–
Data are shown as median and range.
Ag., aggregates; + TRAP, after activation of platelets with TRAP-6; p-values resulti
significant).
§ indicates significantly different values in all patients compared to all controls; * indi
significantly different values in subgroups of patients and controls (pb0.01; Bonferron
shown as percent of the totally counted number of neutrophils/monocytes, CD62P is spatients were investigated to strictly rule out the influence of
acute infections on platelet function.
CF patients showed an increase of soluble P-selectin
(sCD62P) and soluble CD40 ligand (sCD40L) compared with.
patients Young controls Old controls p
41 3–14 15–41
8 n=26 n=29
§†
4–56.4)
30.6§†
(17.4–50.0)
29.4§†
(16.6–60.1)
b0.001
†
2386)
157§†
(16–664)
159§†
(10–634)
b0.001
1)
16§*
(5–62)
8§*†
(2–43)
b0.001
96)
61§*
(9–91)
30§*†
(9–87)
b0.001
2.1)
0.5
(0.0–1.9)
0.3
(0.0–5.3)
0.116
60.4)
45.4
(2.2–60.0)
40.5
(0.9–60.3)
0.628
ng from Kruskal–Wallis test are indicated (pb0.05 was considered statistically
cates significantly different values in the older and younger subgroup; † indicates
i-corrected Mann–Whitney U-test). $Platelet–neutrophil/monocyte aggregates are
hown as percent of CD62P positive platelets without and after TRAP-stimulation.
Table 3
Platelet proinflammatory function in patient subgroups contrasted by the level of systemic inflammation.
Parameter Old patients 15–41 years Old patients 15–41 years Young patients 3–14 years
CRP≤0.46 CRPN0.46 IgG≤1400 IgGN1400 CRP≤0.04 CRPN0.04
17 11⁎ 17 11⁎ 14 12
Soluble CD62P ng/ml 40.3 (25.4–56.4) 41.3 (26.7–51.7) 41.3 (26.7–51.7) 40.3 (25.4–56.4) 40.0 (22.4–52.1) 46.1 (29.3–67.8)
Soluble CD40L pg/ml 370 (57–2386) 294 (57–1392) 294 (57–1392) 370 (82–2886) 441 (82–1444) 447 (133–1228)
Platelet–neutrophil ag. % 26 (6–81) 20 (7–56) 20 (7–56) 26 (6–81) 24 (6–62) 32 (5–85)
Platelet–monocyte ag. % 67 (15–91) 56 (34–96) 67 (34–96) 65 (15–91) 69 (13–92) 80 (16–92)
CD62P % 0.7 (0.0–1.9) 0.3 (0.0–2.1) 0.3 (0.0–1.4) 0.7 (0.0–2.1) 0.7 (0.1–14.5) 0.6 (0.0–2.5)
CD62P+TRAP % 41.6 (2.0–60.4) 37.9 (16.5–51.9) 33.5 (2.0–47.4) 43.6 (22.2–60.4) 38.1 (5.2–51.1) 40.1 (0.8–52.1)
Data are shown as median and range.
ag., aggregates; + TRAP, after activation of platelets with TRAP-6; There was no significant difference of any parameter indicated (pN0.05 for all comparisons). This
means, that platelet proinflammatory parameters were independent from the activity of inflammation.
⁎subgroups with high CRP and high IgG were not identical.
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in very young children and was independent from age and the
activity of inflammation. Both proteins can be detected on the
platelet membrane and in plasma. They are considered to be
mainly platelet-derived and play an important role in platelet
proinflammatory activity [4,16–19]. CD62P expression on
platelet membranes in CF, however, was not altered. ThisFig. 2. Platelet hemostatic function. Panel a shows baseline PAC-1-binding to unstim
activated platelets is demonstrated in Panel b. Both PAC-1-binding to unstimulated a
with higher markers of chronic inflammation. p-values resulting from Kruskal–Wallis
* indicates a significant difference between all patients and controls, ° indicates a sig
Bonferroni-corrected Mann–Whitney U-Test was considered to indicate a significan
not identical.discrepancy has been found previously [20] and might be
explained by the rapid shedding of CD62P from the platelet
surface [21]. Our data clearly demonstrated an activation of
platelet proinflammatory functions in CF.
PLAs form due to platelet activation and platelets facilitate
leukocyte recruitment to the sites of inflammation by direct
interaction with leukocytes and endothelium [4–7]. Thereforeulated platelets in patients and controls subgroups. PAC-1-binding to TRAP-6
nd activated platelets were significantly decreased in older patients and patients
analysis are shown (pb0.05 was considered to indicate a significant difference).
nificant difference between old patients and old controls (pb0.01 resulting from
t difference between subgroups). ‡Subgroups with high CRP and high IgG were
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activity. In this study, the number of PLAs was increased in
CF patients, concordant with previous findings. A significant
difference between the numbers of PLAs was obvious in older
patients only. As demonstrated by this study, the physiological
decrease of PLAs was absent in CF. Therefore the platelet
proinflammatory activity leading to PLA formation increased
relative to healthy individuals with growing age. In a sub-
sequent study platelet leukocyte interaction was investigated in
more detail. The increased number of PLAs in CF could not be
explained by a different expression of leukocyte PSGL-1
mainly responsible for PLA formation [22]. Leukocyte integrin
αMβ2 which was increased in CF in this study seems to play a
minor role for aggregate formation [23].
The mechanisms leading to platelet activation in CF were not
identified in this study. Knowing about the early onset of
inflammation in CF [2], this study showed a systemic increase of
platelet proinflammatory cytokines in very young patients in the
absence of elevated CRP or IgG levels. These platelet-derived
cytokines do not further increase when systemic inflammation,
as evidenced by CRP and IgG levels, gets more severe.
Pulmonary inflammation may lead to a local activation of
platelets via cytokines or damaged endothelium. The local
platelet stimulation in the lung is a possible mechanism to
explain platelet proinflammatory activity in very young CF
patients, in whom systemic inflammation could not be detected
by common methods. Microorganisms (present in CF lungs) are
also able to activate platelets [24]. Our study showed that being
colonised with pseudomonas or S. aureus does not influence
systemic platelet activation. However pharynx colonization, as
investigated in children unable to produce sputum, or sputum
findings do not necessarily indicate a current contribution of the
bacteria to lung inflammation. Especially in young children
there is no suitable way to monitor local pulmonary inflamma-
tion. It would certainly be interesting to do research on the
mechanisms of platelet activation in the lung itself. Realising
such a project, however, will require a suitable animal model.
Systemic inflammation was evident in older patients and
therefore additional systemic platelet activation must be
assumed. The latter may explain the increase of PLAs observed
in older patients.
Chronic inflammation resulted in a decreased activation
(PAC-1-binding) and exocytosis of the integrin αIIbβ3 equiv-
alent to a decrease in platelet procoagulatory function.
Reflecting the results of previous studies [5,12] and the clear
activation of platelet proinflammatory functions in CF in this
study, this decrease of PAC-1-binding to unstimulated and
activated CF platelets, as seen in our study, was a novel and
surprising finding. The more inflammation was present, the less
PAC-1-binding was observed. Furthermore the exocytosis of
the integrin αIIbβ3 (CD41a, receptor of PAC-1) upon
stimulation of CF platelets was reduced, as proven in the
subsequent study including 15 patients. As integrin αIIbβ3 is the
most important platelet protein involved in clot formation, our
data demonstrated a downregulation of platelet procoagulatory
function in CF which started at early age and was further
promoted by the activity of chronic inflammation. PAC-1-binding and other markers of platelet activation were shown to
be altered differently in inflammatory disorders other than CF
previously [25,26]. These findings indicate a complex regula-
tion of platelet function in inflammatory disorders.
This study demonstrated for the first time, an increased
platelet proinflammatory activity at very young age and,
correlating with the activity of inflammation, a reduction of
platelet procoagulatory properties. These findings indicate that
in CF, platelets are regulated to proinflammatory cells and that
this process starts in early childhood, when clinical and
laboratory signs of inflammation are still absent. Previous
studies in cardiovascular, allergic and other diseases suggested a
contribution of platelets to the process of inflammation, the
alteration of bronchi and lung tissue and the recruitment of
leukocytes [4,6–8]. This may also occur in CF and promote
tissue damage. The hypothesis is supported by the beneficial
effects of ibuprofen, a weak platelet inhibitor [27], and the
reduction of platelet proinflammatory lipid thromboxane A2
production by acetylsalicylic acid in CF patients [28,29].
Moreover platelet proinflammatory function seems to be
influenced by steroids in CF, as sCD40L levels were lower in
patients on steroids in this study. Future research is needed to
prove platelet mediated tissue damage and to get more insights
into the mechanisms of platelet regulation and their interaction
with leukocytes. This research may lead us to new beneficial
drugs interfering with platelet–leukocyte interactions and to
new therapeutic strategies.Acknowledgments
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